Catalent buys Pharmapak, Australia
Provides regional packaging capabilities and complements facility in Braeside, Victoria
Catalent Pharma Solutions has acquired Australian packaging firm Pharmapack Technologies to enhance its softgels and capsules business in the country.
Financial details have not been disclosed.
Pharmapak Technologies employs around 100 people, who will be retained along with the management team, and will continue to operate at its existing facility in Dee Why, New South Wales. The company specialises in primary and secondary packaging of oral pharmaceutical dose forms including blisters, bottles and tertiary packaging services.
This acquisition provides regional packaging capabilities and complements Catalent’s facility in Braeside, Victoria, from which the company produces oral dose products including softgels, Vegicaps and OptiShell capsules, for supply throughout Asia Pacific.
Mark Bisset, President of Catalent Asia Pacific, said: 'This acquisition complements our industry-leading oral dosage form development and manufacturing capabilities with a broader range of packaging options, from bulk supply to finished packs.
'Catalent has made substantial recent investments in Asia Pacific with a new facility in China, and last year we celebrated our 40th year in Japan with a new laboratory and the build-out of more manufacturing capacity. This latest investment is in response to strong, local market demand for both pharmaceutical, over-the-counter (OTC) and Complementary Medicine products.'
